title: Inhibited effects of veliparib combined doxorubicin for BEL-7404 proliferation of human liver cancer cell line.
abstract: OBJECTIVE
  To explore inhibition effects of veliparib as PARP inhibitor combined doxorubicin for BEL-7404 proliferation of human liver cancer cell line.
  
  
  METHODS
  BEL-7404 was taken as the object of study and conventional culture was performed. It was treated by doxorubicin and (or) veliparib after 24 h. Cell proliferation rate was detected by four methyl thiazolyl tetrazolium (MTT) assay, cell apoptosis was measured with annexin V-FITC/PI double staining method by flow cytometry, DNA damage degree evaluation by single cell gel electrophoresis assay, and cytosolic C levels of the mitochondrial and cytosol by polyacrylamide gel electrophoresis (Western blotting).
  
  
  RESULTS
  Cell proliferation rate of doxorubicin combined veliparib group was lower than that of the control group and doxorubicin alone treated group significantly (P<0.01), the apoptosis rate was significantly higher than that of the control group and doxorubicin alone treated group (P<0.05). At the same time, DNA damage level of doxorubicin combined with veliparib group was significantly higher than doxorubicin alone treatment group and the control group (P<0.01), and cytochrome C in the cytosol was significantly higher than that of control group and doxorubicin alone treated group (P<0.01).
  
  
  CONCLUSIONS
  Veliparib, PARP inhibitor could inhibit PARP activity, block tumor cell DNA repair, and have significant sensitizing effect for hepatocellular carcinoma cell line BEL-7404 treated with doxorubicin. This might provide a new target for clinical treatment of hepatic carcinoma.
authors: Department of Intervention, Zhongshan Hospital Affiliated to Dalian University, Dalian 116001, China.
authors: Xu
authors: X
authors: Zhao
authors: Department of General Surgery, Zhongshan Hospital Affiliated to Dalian University, Dalian 116001, China.
authors: Yu
authors: Y
authors: Wang
authors: Department of General Surgery, Dalian Beihai Hospital, Dalian 1116021, China.
authors: Jian-Jun
authors: JJ
authors: Gao
authors: Department of General Surgery, Zhongshan Hospital Affiliated to Dalian University, Dalian 116001, China. Electronic address: jiajunyin1106@gmaie.com.
authors: Jia-Jun
authors: JJ
authors: Yin
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000633:toxicity; D017209:Apoptosis / Q000187:drug effects; D001562:Benzimidazoles / Q000494:pharmacology* / Q000633:toxicity; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D045304:Cytochromes c / Q000378:metabolism; D004249:DNA Damage / Q000187:drug effects; D004317:Doxorubicin / Q000494:pharmacology* / Q000633:toxicity; D006801:Humans; D008113:Liver Neoplasms / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D001562:Benzimidazoles; C521013:veliparib; D004317:Doxorubicin; D045304:Cytochromes c
keywords: Cytochrome c; Doxorubicin; Liver cancer; Proliferation rate; Veliparib